Aeterna Zentaris Receives Positive Opinion for Orphan Medicinal Product Designation for AEZS-108 for Treatment of Ovarian Cancer

20-May-2010 - Canada

Aeterna Zentaris Inc. announced that it has received a positive opinion for orphan medicinal product designation from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency, for its compound AEZS-108 for the treatment of ovarian cancer. AEZS-108, the Company's doxorubicin targeted conjugate compound, is currently in a Phase 2 trial in advanced ovarian and advanced endometrial cancer in Europe.

Juergen Engel, Ph. D., President and CEO of Aeterna Zentaris stated, "We are very pleased with AEZS-108 gaining orphan medicinal product designation for ovarian cancer from European authorities, especially after having been recently granted orphan-drug designation by the FDA. This means that with both these orphan designations, AEZS-108 would be provided with extra market exclusivity protection in Europe as well as in the United States for the treatment of ovarian cancer. We now look forward to reporting the final results from our ongoing European Phase 2 study in ovarian and endometrial cancer, later this year."

AEZS-108 represents a new targeting concept in oncology using a cytotoxic peptide conjugate which is a hybrid molecule composed of a synthetic peptide carrier and a well-known cytotoxic agent, doxorubicin. The design of this product allows for the specific binding and selective uptake of the cytotoxic conjugate by LHRH-receptor-positive tumors. The binding of AEZS-108 to cancerous cells that express these receptors results in its accumulation and preferential uptake in the malignant tissue.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

Last viewed contents

Phase-II-Studie für VEGF Trap-Eye zeigt positive Zwischenergebnisse bei altersbedingter Makula-Degeneration - Bayer HealthCare und Regeneron planen Start einer Phase-III-Studie im zweiten Halbjahr 2007

Arena Pharmaceuticals' APD356 Selected as Winner of CONNECT's Most Innovative New Product Award in the Biotech R&D Category

Æterna Zentaris Announces Perifosine Receives FDA Fast Track Designation for Treatment of Refractory Advanced Colorectal Cancer

LegoChem Biosciences and Glycotope Announce Research Collaboration and License Agreement for an Antibody for use as Antibody Drug Conjugate

Heptares grants Shire an exclusive worldwide license to develop and commercialise drug candidates for CNS disorders

Aastrom Biosciences and Zellera AG Announce the Initiation of a Clinical Trial for Bone Grafting in Spain - Aastrom's Proprietary TRCs to be Utilized in Second European Clinical Study to Treat Major Bone Fractures

Akzo Nobel's Wijers: "Top institute for white biotech vital to drive Dutch industrial competitiveness"

Researchers Hone in on Stem Cell that Speeds Healing of Stubborn Diabetes Wounds

Vernalis completes the acquisition of the privately held UK biotech company Ionix Pharmaceuticals

QIAGEN Tests Clinically Verified for the Monitoring of Swine Flu - German Bernhard Nocht Institute Unequivocally Detects Infections with the H1N1 Strain Using the artus Influenza Test

New 'chemical noses' to rid the environment of industrial pollutants

New 'chemical noses' to rid the environment of industrial pollutants